Bisantrene gets a few mentions (FTO MODULATION) in this review of research on metabolism-targeted therapy and immunotherapy. Mason level technical...but we get a wrap...
"Subsequently, more potent inhibitors with potential to improveanti-tumor immunity was developed. CS1/2-induced FTO inhibition not only attenuates leukemia stem cell self-renewal, but reprograms immune responses"
Good to know that while we have some shorter term therapy and revenue possibilities, we also have another iron in the fire in this emerging new area.
Bisnatrene Therapy=
Cancer Killing
Cardio Protecting
Immunotherapy Enhancing
FTO-CS1-CS2-IMMUNOTHERAPY.pdf
- Forums
- ASX - By Stock
- RAC
- RAC media coverage
RAC media coverage, page-2050
-
-
- There are more pages in this discussion • 222 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.83 |
Change
0.020(1.11%) |
Mkt cap ! $310.7M |
Open | High | Low | Value | Volume |
$1.81 | $1.83 | $1.79 | $142.0K | 78.77K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 500 | $1.81 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.83 | 641 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 500 | 1.810 |
3 | 7009 | 1.790 |
1 | 450 | 1.780 |
2 | 16392 | 1.770 |
2 | 1018 | 1.765 |
Price($) | Vol. | No. |
---|---|---|
1.830 | 558 | 1 |
1.840 | 4000 | 2 |
1.845 | 2746 | 1 |
1.860 | 1000 | 1 |
1.870 | 1200 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online